Theranostics
Haematology
lymphoma and rituxumab for marginal zone lymphoma. Zanubrutinib works by blocking the B-cell lymphoma-2 (Bcl-2) protein and blocks the
clinical trial—is available across multiple GenesisCare sites. It compares the targeted therapy TLX591-Tx, in combination with standard care, against standard care alone. The study, sponsored by Telix Pharmaceuticals, is investigating a new treatment approach for men with advanced, PSMA positive metastatic prostate cancer that has not responded to prior therapies. The therapy uses the antibody rosopatamab, which targets PSMA expressing cancer cells and is linked to the radioactive isotope lutetium177, potentially enabling precise delivery of radiation directly to tumour sites. Study Investigator and Nuclear Medicine Physician Dr Aviral Singh shared his perspective on the trial:
Bruton tyrosine kinase (BTK) protein. The rationale for the combination of
zanubrutinib with an anti-CD20 inhibitor is to evaluate whether this will result in a favourable benefit-risk profile and to see if by targeting lymphoma cells in multiple ways is more effective than using one drug alone. The primary endpoint for this study is progression free survival (PFS). Study Investigator, haematologist, Dr Wilf Jaksic had this to say about the study:
2025 has been a year of significant progress in Theranostics, with the Australian oncology clinical trials landscape enabling access to early-phase studies of innovative targeted radionuclide therapies. Our GenesisCare Theranostics team has been at the forefront of this growth, expanding both research and site capabilities and establishing a strong reputation as a leading global provider of Theranostics clinical trials. As a result, GenesisCare has now contributed to more than 37 Theranostics studies. The team is currently managing 13 active studies, three in follow-up, and eight in startup across our network. GenesisCare is committed to ensuring men with prostate cancer have access to new treatment options, with several trials currently open to recruitment. Prostate cancer was the most commonly diagnosed cancer in 2021 and is projected to remain so through 2025. 11 The ProstACT Global trial—a phase III randomised
GenesisCare continues to expand its haematology clinical trial portfolio, with increasing numbers of studies and participating sites throughout 2025. We currently have 8 active haematology studies, with additional trials in the pipeline. Our growing haematology clinical trials program, supported by an expanding suite of Principal Investigators, ensures GenesisCare clinical research remains at the forefront of blood cancer innovation. Our GenesisCare, North Adelaide team is currently working with Principal Investigator, haematologist Dr Wilf Jaksic on a phase 3 clinical trial for relapsed/refractory follicular and marginal zone lymphoma. The BGB-3111- 308 (Mahogany) study is sponsored by BeOne Medicines. The purpose is to compare the effectiveness of the investigational drug zanubrutinib in combination with obinutuzumab for follicular
We were grateful to be able to participate in the Mahogony BGB- 3111-308 study of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab in patients with relapsed/ refractory follicular lymphoma at GenesisCare, North Adelaide. The need for effective and tolerable second-line or later alternative regimens to current immunochemotherapy is potentially addressed with this study.
The study aims to evaluate the safety and potential benefits of PSMA based Theranostics— particularly its ability to improve survival and quality-of-life for patients with advanced disease. This targeted approach may offer a safer and more personalised treatment option and I’m proud to lead this international effort from Perth.
4
8
0 Research projects /registries
0 Publications and presentations
9
17
1 Research projects /registries
2 Publications and presentations
Clinical trials
Investigators
Clinical trials
Investigators
3
8
8
11
31
8
Breast, Lung, Prostate Top disease sites
Lymphoma
Patients in research
Top disease sites
External sponsors
Research sites
Patients in trials
External sponsors
Research sites
20
21
Made with FlippingBook Annual report maker